Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.-论文-万方医学网

第一作者： Annette M,Staiger

第一单位： Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland.

作者： Annette M,Staiger ^[1] ; Marita,Ziepert ^[1] ; Heike,Horn ^[1] ; David W,Scott ^[1] ; Thomas F E,Barth ^[1] ; Heinz-Wolfram,Bernd ^[1] ; Alfred C,Feller ^[1] ; Wolfram,Klapper ^[1] ; Monika,Szczepanowski ^[1] ; Michael,Hummel ^[1] ; Harald,Stein ^[1] ; Dido,Lenze ^[1] ; Martin-Leo,Hansmann ^[1] ; Sylvia,Hartmann ^[1] ; Peter,Möller ^[1] ; Sergio,Cogliatti ^[1] ; Georg,Lenz ^[1] ; Lorenz,Trümper ^[1] ; Markus,Löffler ^[1] ; Norbert,Schmitz ^[1] ; Michael,Pfreundschuh ^[1] ; Andreas,Rosenwald ^[1] ; German,Ott ^[1] ; German High-Grade Lymphoma Study Group

作者单位： Annette M. Staiger, Heike Horn, and German Ott, Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart; Annette M. Staiger and Heike Horn, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Annette M. Staiger and Heike Horn, University of Tuebingen, Tuebingen; Marita Ziepert and Markus Löffler, Institute for Medical Informatics, Statistics and Epidemiology, Universität Leipzig, Leipzig; Thomas F.E. Barth and Peter Möller, Institute of Pathology, Universitätsklinikum Ulm, Ulm; Heinz-Wolfram Bernd and Alfred C. Feller, Haematopathologie Luebeck, Luebeck; Wolfram Klapper and Monika Szczepanowski, Institute of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Monika Szczepanowski, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel; Michael Hummel and Dido Lenze, Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin; Harald Stein, Pathodiagnostik Berlin, Berlin; Martin-Leo Hansmann and Sylvia Hartmann, Dr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt; Georg Lenz, Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, and Cluster of Excellence EXC 1003, Cells in Motion, Münster; Lorenz Trümper, Georg-August Universität, Göttingen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg; Michael Pfreundschuh, Saarland University Medical School, Homburg/Saar; Andreas Rosenwald, Institute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany; David W. Scott, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Sergio Cogliatti, Institute of Pathology, Kantonal Hospital St Gallen, St Gallen, Switzerland. ^[1]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环磷酰胺(Cyclophosphamide);无病生存(Disease-Free Survival);多柔比星(Doxorubicin);依托泊甙(Etoposide);女(雌)性(Female);德国(Germany);生发中心(Germinal Center);人类(Humans);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);男(雄)性(Male);中年人(Middle Aged);泼尼松(Prednisone);原癌基因蛋白质c-bcl-2(Proto-Oncogene Proteins c-bcl-2);原癌基因蛋白质c-bcl-6(Proto-Oncogene Proteins c-bcl-6);原癌基因蛋白质c-myc(Proto-Oncogene Proteins c-myc);存活率(Survival Rate);易位, 遗传(Translocation, Genetic);长春新碱(Vincristine);青年人(Young Adult)

DOI 10.1200/JCO.2016.70.3660

PMID 28525305

发布时间 2022-04-11

检索历史清除

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Journal of clinical oncology

相似文献

Journal of clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Journal of clinical oncology

相似文献

Journal of clinical oncology

相关期刊

检索历史清除